CXCL12 and neoplasm: Importantly, it has been shown that disruption of the CXCR4/CXCL12 axis using CXCR4-specific RNAi or a small molecule inhibitor of CXCR4 AMD3100 led to a decreased tumor vessel density and markedly reduced tumor angiogenesis in a FVB/NJ immunocompetent model of ovarian cancer [47].